Scarica l'app Stockscreener
12.54
16.43%
1.77
Dopo l'orario di chiusura:
12.54
Panoramica
Notizia
Cronologia dei prezzi
Catena di opzioni
Financials
Perché RLAY Giù?
Forum
Previsione
Precedente Chiudi:
$10.77
Aprire:
$10.5
Volume 24 ore:
8.88M
Relative Volume:
3.60
Capitalizzazione di mercato:
$2.24B
Reddito:
$15.36M
Utile/perdita netta:
$-276.48M
Rapporto P/E:
-7.7748
EPS:
-1.6129
Flusso di cassa netto:
$-235.87M
1 W Prestazione:
+23.91%
1M Prestazione:
+28.09%
6M Prestazione:
+140.23%
1 anno Prestazione:
+403.61%
Intervallo 1D:
$10.48
$13.04
Intervallo di 1 settimana:
$9.275
$13.04
Portata 52W:
$1.775
$13.04
Relay Therapeutics Inc Stock (RLAY) Company Profile
Nome
Relay Therapeutics Inc
Settore
Industria
Telefono
617-370-8837
Indirizzo
60 HAMPSHIRE STREET, CAMBRIDGE
Compare RLAY vs VRTX, REGN, ARGX, ALNY, INSM
| Azioni | Prezzo | Cap. di mercato | Reddito | Reddito netto | Flusso di cassa | EPS |
|---|---|---|---|---|---|---|
RLAY
Relay Therapeutics Inc
|
12.54 | 2.24B | 15.36M | -276.48M | -235.87M | -1.6129 |
VRTX
Vertex Pharmaceuticals Inc
|
438.71 | 111.45B | 12.07B | 3.95B | 3.19B | 15.33 |
REGN
Regeneron Pharmaceuticals Inc
|
761.85 | 80.54B | 14.34B | 4.50B | 3.77B | 41.56 |
ARGX
Argen X Se Adr
|
746.42 | 46.32B | 4.16B | 1.29B | 734.26M | 19.58 |
ALNY
Alnylam Pharmaceuticals Inc
|
318.85 | 42.29B | 3.71B | 313.75M | 465.38M | 2.2571 |
INSM
Insmed Inc
|
162.43 | 35.01B | 606.42M | -1.28B | -997.58M | -6.403 |
Relay Therapeutics Inc Stock (RLAY) Upgrades & Downgrades
| Data | Azione | Analista | Modifica della valutazione |
|---|---|---|---|
| 2026-01-26 | Aggiornamento | Oppenheimer | Perform → Outperform |
| 2025-12-12 | Aggiornamento | Wells Fargo | Equal Weight → Overweight |
| 2025-09-04 | Ripresa | Guggenheim | Buy |
| 2025-04-17 | Iniziato | Wells Fargo | Equal Weight |
| 2024-09-10 | Ripresa | Goldman | Buy |
| 2024-09-10 | Aggiornamento | Jefferies | Hold → Buy |
| 2024-09-10 | Downgrade | Oppenheimer | Outperform → Perform |
| 2024-05-10 | Aggiornamento | Barclays | Equal Weight → Overweight |
| 2023-04-20 | Aggiornamento | Jefferies | Underperform → Hold |
| 2023-04-19 | Aggiornamento | Raymond James | Outperform → Strong Buy |
| 2023-04-13 | Iniziato | Raymond James | Outperform |
| 2023-02-03 | Iniziato | Oppenheimer | Outperform |
| 2022-09-30 | Iniziato | Barclays | Equal Weight |
| 2022-09-02 | Iniziato | Stifel | Buy |
| 2022-06-06 | Iniziato | Jefferies | Underperform |
| 2022-02-01 | Iniziato | Berenberg | Buy |
| 2021-07-21 | Iniziato | BofA Securities | Buy |
| 2020-12-15 | Reiterato | H.C. Wainwright | Buy |
| 2020-12-08 | Iniziato | JMP Securities | Mkt Outperform |
| 2020-11-05 | Iniziato | H.C. Wainwright | Buy |
| 2020-08-10 | Iniziato | Cowen | Outperform |
| 2020-08-10 | Iniziato | Goldman | Buy |
| 2020-08-10 | Iniziato | Guggenheim | Buy |
| 2020-08-10 | Iniziato | JP Morgan | Neutral |
Mostra tutto
Relay Therapeutics Inc Borsa (RLAY) Ultime notizie
Aug Highlights: Can Relay Therapeutics Inc scale operations efficiently2026 Short Interest & Weekly High Return Stock Opportunities - baoquankhu1.vn
Relay Therapeutics (RLAY) climbs 16% ahead of cancer treatment update - MSN
Which Is a Better Investment, ACADIA Pharmaceuticals Inc. or Relay Therapeutics, Inc. Stock? - AAII.com
Relay Therapeutics, Inc. (RLAY) stock price, news, quote and history - Yahoo Finance Singapore
Relay Therapeutics (NASDAQ:RLAY) Reaches New 52-Week HighTime to Buy? - MarketBeat
Relay Therapeutics to Present Initial Clinical Data on Zovegalisib in Vascular Anomalies at the International Society for the Study of Vascular Anomalies World Congress 2026 - Sahm
Relay Therapeutics (RLAY) Climbs 16% Ahead of Cancer Treatment Update - insidermonkey.com
Relay Therapeutics to Present Initial Clinical Data on Zovegalisib at Vascular Anomalies Conference - National Today
5 Stocks With Easy 8-20% Gains - Insider Monkey
First zovegalisib results in about 20 vascular anomaly patients due in May - Stock Titan
Relay Therapeutics stock hits 52-week high at $11.52 By Investing.com - Investing.com Canada
Relay Therapeutics (NASDAQ:RLAY) Stock Price Up 6.4%Here's What Happened - MarketBeat
Relay Therapeutics stock hits 52-week high at $11.52 - Investing.com
Earnings Update: Is Relay Therapeutics Inc likely to announce a buybackEarnings Overview Summary & Free Safe Capital Growth Stock Tips - baoquankhu1.vn
Will Relay Therapeutics Inc benefit from government policyQuarterly Profit Report & Community Consensus Picks - baoquankhu1.vn
Assessing Relay Therapeutics (RLAY) Valuation After New ReDiscover Trial Data And FDA Breakthrough Status - simplywall.st
RLAY SEC FilingsRelay Therapeutics, Inc. 10-K, 10-Q, 8-K Forms - Stock Titan
Relay Therapeutics (RLAY) price target increased by 17.50% to 17.43 - MSN
Vanguard realignment reports 0 Relay Therapeutics shares (RLAY) - Stock Titan
Aug Levels: Will Relay Therapeutics Inc benefit from green energy policies2026 Technical Overview & Smart Swing Trading Alerts - baoquankhu1.vn
Is Relay Therapeutics a Buy in 2026? One Institutional Investor Just Made a $6 Million Bet. - AOL.com
PERCEPTIVE ADVISORS LLC Acquires Significant Stake in Relay Ther - GuruFocus
Relay Therapeutics unveils educational resource on mutant selective PI3Kα inhibitor for vascular anomalies - Traders Union
Aug Summary: Will Relay Therapeutics Inc benefit from government policy2026 Macro Impact & Fast Moving Trade Plans - baoquankhu1.vn
HC Wainwright Has Positive Outlook for RLAY Q1 Earnings - MarketBeat
RLAY: HC Wainwright & Co. Raises Price Target to $19.00, Maintai - GuruFocus
H.C. Wainwright raises Relay Therapeutics price target on trial data By Investing.com - Investing.com Australia
Relay Therapeutics (NASDAQ:RLAY) Stock Price Expected to Rise, HC Wainwright Analyst Says - MarketBeat
H.C. Wainwright raises Relay Therapeutics price target on trial data - Investing.com
H.C. Wainwright Maintains Relay Therapeutics(RLAY.US) With Buy Rating, Raises Target Price to $19 - Moomoo
Aug Update: What is the earnings history of Relay Therapeutics IncTrade Analysis Report & Target Return Focused Picks - baoquankhu1.vn
Relay Therapeutics Inc receives Investment Bank Analyst Rating Update By Investing.com - Investing.com Canada
Raymond James reiterates Strong Buy on Relay Therapeutics stock By Investing.com - Investing.com Canada
Profit Review: Can Relay Therapeutics Inc sustain its profitability2026 Catalysts & Risk Adjusted Buy and Sell Alerts - baoquankhu1.vn
Relay Therapeutics Price Target Raised to $17.00 - National Today
Relay Therapeutics (RLAY) — Perceptive entities report 5.3% stake - Stock Titan
Nextech Invest Increases Relay Therapeutics Stake in Q4 2025 | Portfolio UpdateNews and Statistics - IndexBox
Is Relay Therapeutics a Buy in 2026? One Institutional Investor Just Made a $6 Million Bet. - The Motley Fool
Relay Therapeutics (RLAY) Receives a Buy from Wells Fargo - The Globe and Mail
Portfolio Update: Is Relay Therapeutics Inc a speculative investmentEarnings Growth Report & Fast Entry and Exit Trade Plans - baoquankhu1.vn
RLAY: Citizens Raises Price Target to $17, Maintains Market Outp - GuruFocus
Relay Therapeutics price target raised to $17 from $15 at Citizens - TipRanks
Citizens Jmp Issues Positive Forecast for Relay Therapeutics (NASDAQ:RLAY) Stock Price - MarketBeat
Relay Therapeutics (RLAY) Sees Price Target Raised by Wells Farg - GuruFocus
Wells Fargo & Company Boosts Relay Therapeutics (NASDAQ:RLAY) Price Target to $17.00 - MarketBeat
Wells Fargo Maintains Relay Therapeutics(RLAY.US) With Buy Rating, Raises Target Price to $17 - Moomoo
Citizens JMP Maintains Relay Therapeutics(RLAY.US) With Buy Rating, Raises Target Price to $17 - Moomoo
Oppenheimer reiterates Relay Therapeutics stock rating on trial data By Investing.com - Investing.com Canada
Relay Therapeutics Inc Azioni (RLAY) Dati Finanziari
Reddito
Reddito netto
Flusso di cassa
EPS
0.49%
1.47%
Apri su Yahoo
|
Apri su Google
|
Aperto in Finviz
|
Apri in MarketWatch
|
Aperto a EDGAR
|
Aperto su Reuters
Capitalizzazione:
|
Volume (24 ore):